Format

Send to

Choose Destination
See comment in PubMed Commons below
Gynecol Endocrinol. 2013 Mar;29(3):219-21. doi: 10.3109/09513590.2012.738726. Epub 2012 Nov 16.

Gonadotropin releasing hormone agonist and levonorgestrel-intrauterine device followed by in vitro fertilization program as management strategy for an infertile endometrial cancer patient: a case report.

Author information

1
Department of Obstetrics and Gynecology, IRCCS-Arcispedale S. Maria Nuova of Reggio Emilia, University of Modena and Reggio Emilia, Reggio Emilia, Italy. nucerags@gmail.com

Abstract

BACKGROUND:

A progressive delay in the age of first conception results in an increased frequency of endometrial cancer patients in reproductive age and desiring childbearing.

CASE:

A 38-year-old infertile woman with stage I endometrioid adenocarcinoma was treated with gonadotropin releasing hormone agonist (GnRHa) and levonorgestrel-releasing intrauterine device (LNG-IUD). After disease remission, she underwent a controlled ovarian stimulation for standard in vitro fertilization (IVF) program and had a pregnancy delivering a healthy male baby. Total laparoscopic hysterectomy with bilateral salpingo-oophorectomy was performed four months after delivery. The patient is free of disease after 3-year follow-up.

CONCLUSION:

GnRHa plus LNG-IUD followed by IVF program is a safe and effective fertility-sparing strategy to manage infertile patients with stage I endometrial cancer.

PMID:
23153053
DOI:
10.3109/09513590.2012.738726
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center